Evidence map›Paper›PMID 38895223›Full record

ArticlebioRxiv : the preprint server for biology2024

Assessing the impact of autologous neutralizing antibodies on rebound dynamics in postnatally SHIV-infected ART-treated infant rhesus macaques.

Ellie Mainou, Stella J Berendam, Veronica Obregon-Perko, Emilie A Uffman, Caroline T Phan, George M Shaw, Katharine J Bar, Mithra R Kumar, Emily J Fray, Janet M Siliciano and 8 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Ellie MainouDepartment of Biology, Pennsylvania State University, University Park, PA, USA.
Stella J BerendamGlaxoKlineSmith, Rockville, MD, USA.
Veronica Obregon-PerkoFlowJo, Altanta, GA, USA.
Emilie A UffmanDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
Caroline T PhanDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
George M ShawPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Katharine J BarPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Mithra R KumarDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Emily J FrayDepartment of Biochemistry and Molecular Biology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Janet M SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert F SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Guido SilvestriYerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Sallie R PermarDepartment of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
Genevieve G FoudaDepartment of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
Janice McCarthyDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.
Ann ChahroudiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Cliburn ChanDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.
Jessica M ConwayDepartment of Mathematics, Pennsylvania State University, University Park, PA, USA.

Funding

The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeysP01AI131276 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI PERMAR, SALLIE R. · 2017 to 2021
$8.3M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine DesignR01AI160607 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2021 to 2024
$3.2M
Quantitative Methods for HIV/AIDS ResearchR25AI140495 · NIAID · DUKE UNIVERSITY · PI Cliburn C Chan, Gina-Maria Pomann · 2018 to 2026
$2.8M
SIV cervicovaginal transmission dynamicsR21AI143443 · NIAID · PENNSYLVANIA STATE UNIVERSITY, THE · PI CONWAY, JESSICA M · 2020 to 2021
$427k
NIAID NIH HHS P01 AI131276NIAID NIH HHS R01 AI160607NIAID NIH HHS R21 AI143443NIAID NIH HHS R25 AI140495NIH HHS R01 OD011095
6 · The paper itself

Abstract

The presence of antibodies against HIV in infected children is associated with a greater capacity to control viremia in the absence of therapy. While the benefits of early antiretroviral treatment (ART) in infants are well documented, early ART may interfere with the development of antibody responses. In contrast to adults, early treated children lack detectable HIV-specific antibodies, suggesting a fundamental difference in HIV pathogenesis. Despite this potential adverse effect, early ART may decrease the size of the latent reservoir established early in infection in infants, which can be beneficial in viral control. Understanding the virologic and immunologic aspects of pediatric HIV is crucial to inform innovative targeted strategies for treating children living with HIV. In this study, we investigate how ART initiation time sets the stage for trade-offs in the latent reservoir establishment and the development of humoral immunity and how these, in turn, affect posttreatment dynamics. We also elucidate the biological function of antibodies in pediatric HIV. We employ mathematical modeling coupled with experimental data from an infant nonhuman primate Simian/Human Immunodeficiency Virus (SHIV) infection model. Infant Rhesus macaques (RMs) were orally challenged with SHIV.C.CH505 375H dCT four weeks after birth and started treatment at different times after infection. In addition to viral load measurements, antibody responses and latent reservoir sizes were measured. We estimate model parameters by fitting viral load measurements to the standard HIV viral dynamics model within a nonlinear fixed effects framework. This approach allows us to capture differences between rhesus macaques (RMs) that develop antibody responses or exhibit high latent reservoir sizes compared to those that do not. We find that neutralizing antibody responses are associated with increased viral clearance and decreased viral infectivity but decreased death rate of infected cells. In addition, the presence of detectable latent reservoir is associated with less robust immune responses. These results demonstrate that both immune response and latent reservoir dynamics are needed to understand post-rebound dynamics and point to the necessity of a comprehensive approach in tailoring personalized medical interventions.

Identifiers

PMID38895223
PMCPMC11185557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.